Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care
Clinical Endocrinology · 2024
DOI: 10.1111/cen.14992 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Chamila Balagamage und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Transition to Adult Care. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Medical Sciences.
Abstract (Originalsprache)
The adolescent period is characterised by fundamental hormonal changes, which affect sex steroid production, cortisol metabolism and insulin sensitivity. These physiological changes have a significant impact on patients with congenital adrenal hyperplasia (CAH). An essential treatment aim across the lifespan in patients with CAH is to replace glucocorticoids sufficiently to avoid excess adrenal androgen production but equally to avoid cardiometabolic risks associated with excess glucocorticoid intake. The changes to the hormonal milieu at puberty, combined with poor adherence to medical therapy, often result in unsatisfactory control exacerbating androgen excess and increasing the risk of metabolic complications due to steroid over‐replacement. With the physical and cognitive maturation of the adolescent with CAH, fertility issues and sexual function become a new focus of patient care in the paediatric clinic. This requires close surveillance for gonadal dysfunction, such as irregular periods/hirsutism or genital surgery‐associated symptoms in girls and central hypogonadism or testicular adrenal rest tumours in boys. To ensure good health outcomes across the lifespan, the transition process from paediatric to adult care of patients with CAH must be planned carefully and early from the beginning of adolescence, spanning over many years into young adulthood. Its key aims are to empower the young person through education with full disclosure of their medical history, to ensure appropriate follow‐up with experienced physicians and facilitate access to multispecialist teams addressing the complex needs of patients with CAH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, University of Birmingham, Birmingham, UK.
- Department of Endocrinology and Diabetes, Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
- The Medical School, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
- Department of Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
- Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Förderung
- Academy of Medical Sciences
Zitieren
APA
Balagamage, C., Arshad, A., Elhassan, Y. S., Ben Said, W., Krone, R. E., Gleeson, H., & Idkowiak, J. (2024). Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care. Clinical Endocrinology. https://doi.org/10.1111/cen.14992
Vancouver
Balagamage C, Arshad A, Elhassan YS, Ben Said W, Krone RE, Gleeson H, et al. Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care. Clinical Endocrinology. 2024. doi:10.1111/cen.14992
BibTeX
@article{Balagamage2024,
author = {Balagamage, Chamila and Arshad, Amynta and Elhassan, Yasir S and Ben Said, Wogud and Krone, Ruth E and Gleeson, Helena and Idkowiak, Jan},
title = {Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care},
journal = {Clinical Endocrinology},
year = {2024},
doi = {10.1111/cen.14992}
}
EUVIMED